← back to search

Mohit Butaney

Henry Ford Hospital · US
Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, RNA modifications and cancer, and Prostate Cancer Diagnosis and Treatment.
h-index
28
citations
8,343
works
219
NIH funding
primary concept
email

Recent publications

Quality of Bladder Cancer Information on YouTube
European Urology 2020cited by 107position: middledoi
Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers
JAMA Oncology 2019cited by 300position: middledoi
Epidemiology of genitourinary foreign bodies in the united states emergency room setting and its association with mental health disorders
International Journal of Impotence Research 2019cited by 35position: middledoi
Patient Attitudes Toward Testicular Prosthesis Placement After Orchiectomy
American Journal of Men s Health 2019cited by 20position: middledoi
Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer
Journal of Thoracic Oncology 2015cited by 289position: middledoi
Noninvasive Detection of Response and Resistance in <i>EGFR</i> -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA
Clinical Cancer Research 2014cited by 780position: middledoi
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Cancer Discovery 2013cited by 1,235position: middledoi
Clinical, Pathologic, and Biologic Features Associated with <i>BRAF</i> Mutations in Non–Small Cell Lung Cancer
Clinical Cancer Research 2013cited by 368position: middledoi
Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions
Journal of Thoracic Oncology 2013cited by 358position: middledoi
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
Nature 2012cited by 449position: middledoi
Reactivation of ERK Signaling Causes Resistance to EGFR Kinase Inhibitors
Cancer Discovery 2012cited by 290position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Pasi A. Jänne · Harvard University5 papers (2012–2015)Geoffrey R. Oxnard · Boston Medical Center3 papers (2013–2015)Lynette M. Sholl · Harvard University3 papers (2012–2015)David M. Jackman · AbbVie (United States)3 papers (2013–2015)Bruce E. Johnson · Zhejiang University2 papers (2013–2013)Mizuki Nishino · Harvard University2 papers (2013–2013) · 2 papers (2013–2015)Nannan Thirumavalavan · University Hospitals Cleveland Medical Center2 papers (2019–2019)Suzanne E. Dahlberg · Boston Children's Hospital2 papers (2013–2015)Stacy Loeb · Institute of Population and Public Health1 papers (2020–2020)Paul T. Kirschmeier · Center for Cancer Research1 papers (2014–2014)Neal I. Lindeman · Cornell University1 papers (2013–2013) · 1 papers (2013–2013) · 1 papers (2014–2014)Stephen J. Freedland · Cedars-Sinai Medical Center1 papers (2019–2019)Sumanta K. Pal · City of Hope1 papers (2019–2019)Adithya Balasubramanian · The University of Melbourne1 papers (2019–2019)Chunxiao Xu · Hebei North University1 papers (2012–2012)Dawn Walter · New York University1 papers (2020–2020) · 1 papers (2020–2020)